Pyrotinib + Docetaxel
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-squamous NSCLC
Conditions
Non-squamous NSCLC, HER2 Exon 20 Mutation
Trial Timeline
Sep 11, 2020 → Dec 6, 2024
NCT ID
NCT04447118About Pyrotinib + Docetaxel
Pyrotinib + Docetaxel is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Non-squamous NSCLC. The current trial status is completed. This product is registered under clinical trial identifier NCT04447118. Target conditions include Non-squamous NSCLC, HER2 Exon 20 Mutation.
What happened to similar drugs?
3 of 20 similar drugs in Non-squamous NSCLC were approved
Approved (3) Terminated (2) Active (15)
❌Camrelizumab;Pemetrexed and Carboplatin; Famitinib; + Camrelizumab;Pemetrexed and Carboplatin;PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04447118 | Phase 3 | Completed |
Competing Products
20 competing products in Non-squamous NSCLC